Charles River Laboratories International is scheduled to report second-quarter 2026 results on August 5 before market open. The Zacks Consensus Estimate for revenues is $970.8 million, indicating a 5.9% decline from the prior year, while the EPS estimate of $2.72 suggests a 12.8% year-over-year drop. The Research Models and Services segment likely faced pressure from lower small model sales and constrained occupancy at CRADL, though demand in China remained solid, and the Discovery and Safety Assessment segment is expected to see a 5.5% revenue decline partly due to site consolidation and the divestiture of certain European assets to IQVIA for roughly $145 million. Manufacturing Solutions revenues are projected to decrease 8.2%, impacted by the completed sale of the CDMO and Cell Solutions businesses to GI Partners for up to $50 million in contingent payments. Charles River carries a Zacks Rank #2 and an Earnings ESP of +1.43%, suggesting a higher chance of beating estimates.
Charles River LaboratoriesExpected revenue decline of 5.9% and EPS drop of 12.8% in upcoming earnings report.
IQVIA Holdings Inc
